## TABLES

Table I.1  Clinical Areas in QA Tools System By Covered Population Group ......................................................5

Table I.2  Dates Expert Panels Convened ..............................11

Table I.3  Distribution of Indicators (%) by Level of Evidence .......12

Table I.4  Distribution of Indicators (%) by Type of Care ............13

Table I.5  Distribution of Indicators (%) by Function of Medicine ....13

Table I.6  Distribution of Indicators (%) by Modality .................14

Table I.7  Clinical Areas Covered by each Expert Panel ...............15

Table I.8  Clinical Guidelines versus Quality Indicators .............18

Table I.9  Disposition of Proposed Cardiopulmonary Quality Indicators by Strength of Evidence .......................20

Table I.10 Distribution of Final Cardiopulmonary Quality Indicators by Type of Care, Function, and Modality .......24

Table 5.1  Cessation Rates for Various Intensities of Person-to-Person Contact (N = 56 studies) .........................120

Table 5.2  Cessation Rates by Number of Person-to-Person Treatment Sessions (N = 55 studies) .........................120

Table 5.3  Summary of Nicotine Patch Meta-analyses Efficacy Results (N = 5 meta-analyses) ..............................122

Table 5.4  Summary of Nicotine Gum Meta-analyses* (n = 3 meta-analyses) ................................................122

Table 5.5  Correlation of Study Characteristics with Cessation Rates at 12 Month Follow-up ..............................123

Table 11.1 High Blood Pressure Diagnostic Staging System ..........219

## FIGURES

Figure I.1 - Sample Panelist Summary Rating Sheet......................10

Figure I.2 - Sample Rating Results Sheet..............................22